Abstract: In a pixel circuit (10), TFTs (12) to (16) are connected and driven such that a threshold voltage Vth of a TFT (11), which is a drive transistor, can be held in a threshold holding capacitor (19) having a capacitance value c1, voltages, including a data potential Vdata representing an image to be displayed, can be held in a data holding capacitor (18) having a capacitance value c2, and charges in the data holding capacitor (18) and the threshold holding capacitor (19) are redistributed at the time of light emission. As a result, a potential obtained by multiplying the data potential Vdata by c1/(c1+c2) is provided to a gate potential of the TFT (11).

Abstract: The present invention relates to biomarker responsive to treatment with an anti-Thymic Stromal Lymphopoietin (TSLP) antibody.

Abstract: Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

Abstract: A mobile station communicates with a base station controlling over a cell containing a plurality of sectors. The mobile station also receives, from a base station, data of synchronization channels which includes sector specific codes respectively corresponding to sector identification numbers for identifying the sectors. In addition, the mobile station performs synchronization detection with reference to the data of synchronization channels, where the data of the synchronization channels mapped to a plurality of predetermined symbols at intervals of a half period of a frame and a plurality of predetermined subcarriers are specific to respective sectors in the same cell and common among adjacent cells.

Abstract: In its many embodiments, the present invention provides certain C2-carbocyclic iminothiazine dioxide compounds, including compounds Formula (I); or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, ring A, RA, m, ring B, RB, n, ring C, RC and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

Abstract: A prediction vector generation device generating a prediction vector of a disparity vector of a target block in a non-base viewpoint image includes a conversion pixel determination unit determining at least one pixel position in a depth block corresponding to the target block in a depth map corresponding to the non-base viewpoint image, a disparity vector conversion unit calculating a representative value of a depth value of the at least one pixel position determined by the conversion pixel determination unit and converting the representative value into a disparity vector, and a prediction vector determination unit generating the prediction vector of the disparity vector of the target block by using the disparity vector generated by the disparity vector conversion unit. This prediction vector generation device provides good encoding efficiency and suppresses increases in the amount of computation.

Abstract: An organic electroluminescent display device has a display region where image display is performed and a frame region surrounding said display region. The organic electroluminescent display device includes: a first substrate; a second substrate disposed facing said first substrate; an organic electroluminescent element provided on said first substrate in the display region; and a sealing film on said first substrate in the frame and display regions so as to cover said organic electroluminescent element, a surface of the sealing film in the frame region being hydrophilic.

Abstract: A terminal apparatus communicates with a base station apparatus by using a plurality of cells including at least a primary cell and a secondary cell. The terminal apparatus decodes a PDCCH with downlink control information format in which at least a transmission power control command field is included, transmits a PUCCH on the primary cell, and determines transmission power of the PUCCH on the primary cell based on at least a PUCCH power control adjustment parameter. The PUCCH power control adjustment parameter is calculated by accumulating at least a value indicated by the transmission power control command field, and in a case where the terminal apparatus receives a random access response message for the primary cell, the transmission power control circuitry is configured to and/or programmed to reset the PUCCH power control adjustment parameter.

Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

Abstract: A heat exchanger includes a fin, the fin including a metal base and a porous anodized layer formed on the metal base. A surface of the porous anodized layer has a submicron-order uneven structure, the uneven structure including a plurality of recessed portions whose two-dimensional size viewed in a normal direction of the surface is more than 100 nm and less than 500 nm.

Abstract: The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an A? pathology and/or a symptom or symptoms thereof. Non-limiting examples of such A? pathologies, including Alzheimer's disease, are disclosed herein.

Abstract: A management system includes: a management device; and a terminal device. The management device includes: an acquisition unit that acquires device identification information and usage information, the device identification information identifying a heat cooking appliance, the usage information being obtained according to usage of the heat cooking appliance; and a tabulation unit that tabulates, for each store in which the heat cooking appliance corresponding to the device identification information that has been acquired by the acquisition unit is installed, the usage information having been acquired by the acquisition unit. The terminal device acquires tabulated result tabulated by the tabulation unit, and outputs, to an output, the acquired tabulated result.

Abstract: The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

Abstract: A conductive element includes: a first conductive film; a second conductive film connected to the first conductive film; a first insulating film covering the first conductive film and disposed in a layer below the second conductive film, the first insulating film having a contact hole exposing at least an edge face of the first conductive film and thereby connecting the second conductive film to the first conductive film; a second insulating film disposed in a layer above the second insulating film so as to straddle the contact hole; and a third conductive film disposed in a layer above the second conductive film with the second insulating film between the second and third conductive films, the third conductive film having a conductive film opening that contains a location overlapping the edge face of the first conductive film in a plan view.

Abstract: Antibodies that bind the apple 2 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa are described.

Abstract: The invention provides methods and compositions for improving production of exogenous polypeptides in large scale culture of mammalian host cells. The methods and compositions utilize RNA interference to inhibit expression of one or more specific host cell proteins. The present invention is based on the identification of specific mammalian genes and sequences therein that are useful as RNAi targets to enhance the production of exogenous proteins in mammalian cell culture.

Abstract: The present disclosure provides a method in a base station. The method comprises: determining resources for transmitting system information to a Machine Type Communication (MTC) User Equipment (UE), the system information comprising a System Information Block Type 1 (SIB1) message and other system information messages; and transmitting the system information to the MTC UE over the determined resources, the transmission comprising an initial transmission and one or more retransmissions. The resources for the initial transmission and the one or more retransmissions of the other system information messages are indicated by the SIB1 message or predetermined.

Abstract: In a remote simultaneous viewing system, zapping for a different group that views a content having the same attribute as that of a content viewed by a belonging group of a user is enabled. A content reproduction portion (22) that reproduces a content; and a group switching portion (25) that switches a belonging group of a user to a different group that views a content having the same attribute as that of the reproduced content are included.

Abstract: To mitigate interference by using effective knowledge or information as to an interference signal, there is provided a base station apparatus including a higher layer which configures, in a terminal apparatus, first interference information used in the terminal apparatus in order to mitigate interference from a cell-specific reference signal and at least one of second interference information used in the terminal apparatus in order to mitigate interference from a downlink shared channel, third interference information used in the terminal apparatus in order to mitigate interference from a downlink control channel, and fourth interference information used in the terminal apparatus in order to mitigate interference from an enhanced downlink shared channel, in which each of the second interference information, the third interference information, and the fourth interference information is configured in a case where the first interference information is being configured.

Abstract: Provided is a terminal apparatus that communicates with a base station apparatus, including: a control unit that determines a transmit power that is available for application in a first Cell Group (CG), by performing comparison with a first upper limit value and based on the smaller of the transmit power and the first upper limit value, in a case where transmission in a subframe i1 in the first CG overlaps transmission in subframes i2?1 and i2 in a second CG, in which the first upper limit value includes a maximum output power among at least subframes that overlap.